Gilead Sciences has secured regulatory approval from the US Food and Drug Administration for Bixlenvo, a new once-daily single-tablet HIV treatment combining two established compounds.
The pill pairs bictegravir, the active backbone of Gilead’s blockbuster HIV drug Biktarvy, with lenacapavir, a first-in-class capsid inhibitor central to the company’s HIV strategy.
Bixlenvo is specifically designed for adults living with HIV who are already virologically suppressed but cannot use currently available single-tablet treatment options.
Gilead estimates that population accounts for 5% or more of individuals living with HIV in the United States, representing a meaningful gap in available treatment choices.
The approval marks Bixlenvo as the first single-tablet regimen approved for this particular group of patients, according to the company’s announcement.
Bictegravir is an integrase inhibitor widely recognised for its high barrier to resistance, while lenacapavir introduces a novel mechanism of action without cross-resistance to existing antiretrovirals.
The combination is intended to reduce treatment burden for patients already achieving viral control while maintaining long-term suppression through a simplified once-daily regimen.
The list price for Bixlenvo has been set at $4,595 for a 30-day supply before any discounts or rebates are applied, in line with comparable daily single-tablet HIV treatments on the market.
Patients without health insurance may be eligible to receive Bixlenvo at no cost through Gilead’s patient assistance programme, while those with commercial or private insurance may qualify for co-pay support.
Bixlenvo forms part of Gilead’s broader strategy to build a flexible portfolio of HIV treatments centred on lenacapavir, spanning daily pills, weekly oral regimens, and long-acting injectable therapies.
The company’s goal is to give patients greater flexibility in choosing how they manage their condition, reflecting an industry-wide shift toward more personalised HIV care approaches.
Lenacapavir has become a cornerstone of Gilead’s long-term HIV pipeline, with the company investing significantly in expanding the compound’s applications across both treatment and prevention settings.